Jazz and Redx have reached an agreement on a milestone inhibitor

Jazz Pharmaceuticals and Redx have announced the start of clinical trials for a pan-RAF inhibitor.

The US Food and Drug Administration (FDA) has approved an application for JZP815, according to Ireland-based Jazz Pharmaceuticals and Redx.

A pan-RAF inhibitor is being developed for the treatment of solid tumours and hematologic malignancies with mutations in the MAPK pathway. This allows Jazz to move forward with starting a clinical trial for JZP815, which will result in a $5 million payment from Jazz to Redx.

The payment was made under the terms of a deal in which Jazz purchased Redx's pan-RAF inhibitor programme, which was announced on July 10, 2019. The payment comes on top of the $6.5 million already received under the agreement for development activities up to the completion of IND-enabling studies.

In the meantime, Redx is still eligible for research, regulatory, and commercial milestone payments, as well as incremental tiered royalties depending on future net sales.

JZP815 has a distinct mode of action, and Jazz plans to evaluate it as a treatment for a variety of hard-to-treat solid tumours with high unmet patient needs. JZP815 is expected to start a phase 1 clinical trial in the near future, and when it does, it will be the fifth Redx drug to reach the clinic.

Redx's CEO, Lisa Anson, gushed: "I am overjoyed that the IND application for JZP815, a pan-RAF inhibitor, has been approved. Redx's Jazz will be the fifth medication candidate discovered by Redx to enter the clinic when it begins its clinical trial, demonstrating our world-class research and development capabilities. We respect our great partnership with Jazz Pharmaceuticals and look forward to continuing to collaborate with them."

Jazz Pharmaceuticals' Executive Vice President, Rob Iannone, added: "We're excited to start a clinical development for JZP815, a precision pan-RAF inhibitor with a distinct mode of action. JZP815 could be a game-changer in the pan-RAF inhibitor family because it doesn't cause paradoxical pathway activation, which can promote cancer growth."

A separate partnership agreement exists between Jazz and Redx to discover and develop pharmaceutical candidates in the RAS-RAF-MAP kinase pathway.

World BI Group examines how research like this could affect drug clinical trials and innovation and all the challenges that come along with it. This year's Clinical Trials Innovation Programmeswill highlight the future of clinical trials and drug development post-COVID and will feature tailored sessions presented by the leading experts from across the globe, so if you’re someone interested in the pharmaceutical industry, we encourage you to join the Clinical Trials Innovation Programmes which is a prominent platform for interacting with the world's most influential and dynamic professionals. With the Clinical Trials Innovation Programmes, learn how modernization in R&D processes is fundamentally changing what clinical trials research will look like in the next two to five years. So, join us at the19th Clinical Trials Innovation Programmes Taking place at the 05-06 October in Hilton Munich Airport, Germany and 20th Clinical Trials Innovation Programmes taking place at 26- 27 October in The Westin Copley Place Boston, MA for an in-person experience and two days of top-level strategic content and current scientific insights, networking, and discussions with top global pharmaceutical R&D executives. We are bringing together the best in the industry to help you learn and grow, and accelerate your drug development journey. This event will give you a chance to attend and get a complete learning experience about the challenges and their solutions from experts in the field. Register to meet new clients, build your brand, get a handle on the market and drive new business.

Source: https://www.pharmatimes.com/